H
business
H
HOYONEWS
HomeBusinessTechnologySportPolitics
Others
  • Food
  • Culture
  • Society
Contact
Home
Business
Technology
Sport
Politics

Food

Culture

Society

Contact
Facebook page
H
HOYONEWS

Company

business
technology
sport
politics
food
culture
society

CONTACT

EMAILmukum.sherma@gmail.com
© 2025 Hoyonews™. All Rights Reserved.
Facebook page

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

3 days ago
A picture


The US drugmaker Merck has scrapped a £1bn London research centre and is laying off 125 scientists in the capital this year, in a big blow to the UK’s important life science sector.Keir Starmer’s government has described life sciences as “one of the crown jewels of the UK economy” and the previous Conservative government had vowed to turn the country into a “global science and technology superpower” by 2030.The planned new lab, called the UK Discovery Centre, at the Belgrove House site opposite St Pancras and King’s Cross stations, was already under construction and scheduled to open in two years’ time.It had been expected to employ about 800 people overall, including 180 scientists.As part of its U-turn, Merck, known as MSD in Europe, will vacate laboratories at the nearby London Bioscience Innovation Centre, which hosts more than 60 life science companies, and the neighbouring Francis Crick Institute by the end of 2025, with the loss of about 125 scientific jobs.

The New Jersey-based company said it would move the research operations to other sites.It is unclear where in the world it would be, but pharmaceutical companies are under pressure from Donald Trump to invest more in the US.The company declined to provider further details.In a statement, MSD announced “plans to discontinue discovery research operations in the UK and that it no longer plans to occupy the Belgrove House site at King’s Cross”.“This … reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments,” it said.

MSD had previously said the research centre would build on the company’s 100-year heritage in the UK, close to London’s Knowledge Quarter and its Moorgate headquarters.It will keep its HQ and a large animal health site in Milton Keynes.Lengthy negotiations between the government and the industry over the cost of medicines for the UK broke down last month.Under the voluntary pricing and access scheme, companies agree to pay back a certain amount of revenue they make from newer, branded drugs.In 2023, the rebate rate rose to 23.

5%, which compares with 5.7% in France and 7% in Germany.Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), said: “This is a real blow to the UK’s life sciences ambitions.No one wants to hear that successful and innovative companies like MSD are reducing their investment and footprint in the UK.”Referring to a recent survey from Deloitte, and the UK’s trade deal with the US, a government spokesperson said: “The UK has become the most attractive place to invest in the world, but we know there is more work to do.

Through our life sciences sector plan, we’re taking decisive action to further unlock innovation, drive investment and boost growth.”The news came as a report showed that the UK had lost ground to rivals in the global race for pharmaceutical investment and research.Investment in life sciences research and development (R&D) in the UK has underperformed against global trends since 2018, according to the study from the ABPI and the consulting firm PwC.It said a significant slowdown began in 2020, when the rate of growth in R&D investment fell to 1.9% annually, down from 6.

3% in the three preceding years and lagging behind the global average of 6,6%,R&D investment by the pharmaceutical industry even fell in 2023, the final year of the study, by nearly £100m,At £795m, investment by foreign life sciences companies in the UK was 58% lower in 2023 than in 2017, when it stood at £1,9bn.

This meant that the country declined in global rankings from second place in 2017 and 2021 to seventh place in 2023.Sign up to Business TodayGet set for the working day – we'll point you to all the business news and analysis you need every morningafter newsletter promotionThe UK has also fallen behind on clinical trials of new medicines.It ranked eighth for late-stage industry trials in 2023, down from fourth in 2017, although there were “small signs of improvement” in 2023, according to the report.Rippon Ubhi, who runs Sanofi’s UK and Ireland business and the French company’s speciality care division, said: “The findings in this report paint a concerning picture for UK patients and our economy.“The UK is increasingly being viewed as ‘uninvestable’ in global boardrooms due to unprecedented [NHS] clawback rates and restrictive patient access to medicines.

While other countries are actively investing in innovative medicines for patients, the UK is falling behind.”The UK head of the Swiss pharmaceutical firm Novartis, Johan Kahlström, has also said high costs means the UK is “largely uninvestable,”, while the health secretary, Wes Streeting, has pledged that he will not allow firms to “rip off” taxpayers.The government has set a target to position the UK as the leading life sciences economy in Europe by 2030 and third globally by 2035, while the chancellor, Rachel Reeves, has said the UK is at the forefront of developments in the sector.Torbett said: “The UK has a world-class science base and the potential to lead globally in developing the next generation of medicines and vaccines.But without a more competitive environment for investment, we risk losing out to other countries making bold moves to attract internationally mobile investment.

”Only 37% of new medicines are made fully available for their licensed indications in the UK, compared with 90% in Germany,ABPI data shows that more than 60 medicines did not launch in the UK or were delayed between 2019-20 and 2022-23,
businessSee all
A picture

Stagnant GDP shows scale of challenge for Rachel Reeves at autumn budget

“Our economy isn’t broken, but it does feel stuck,” is the message from Rachel Reeves.Having made rebooting the economy the No 1 priority for government, it is a brutally honest assessment from a chancellor more than a year into the job.The latest GDP figures, released on Friday, highlight the scale of the challenge for Reeves at her autumn budget. Growth flatlined in July, slowing from 0.4% in June, as the economy struggled for momentum over the summer

1 day ago
A picture

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

A senior pharmaceuticals executive has called on the government to come up with a “proper” roadmap for raising spending on new medicines, saying Britain is “not a good place” to develop or sell drugs.Paul Naish, the UK head of market access for the French company Sanofi, said Britain was “at a critical point”.He added: “We’ve still got the best universities, we’ve got some of the best scientists in the world, but it’s not a good place to do the development work for medicines. It’s an expensive place to operate, and it’s a terrible place to sell medicines.”The drugmaker MSD, known as Merck in the US, this week ditched its under-construction £1bn research centre in London

1 day ago
A picture

Business rates rise would put hundreds of big shops at risk, say UK retailers

Up to 400 large shops are at risk of closure with as many as 100,000 jobs at risk if the government goes ahead with plans to hit stores with higher business rates, retailers have warned.Some of the UK’s largest retail premises, including supermarkets and department stores, would face higher property tax charges under new rules being considered by the government before November’s budget.The higher charges for larger sites, including warehouses, offices and other premises, are intended to pay for discounts for smaller business properties, such as independent retailers, cafes and pubs, after the Labour government pledged to make the business rates system fairer.The bosses of big retailers including John Lewis, Lidl and B&Q met the chancellor, Rachel Reeves, last week to ask her to exclude retail from the surcharge.The new rules are targeted at all business premises with a rateable value – a figure linked to rents – of more than £500,000

1 day ago
A picture

MPs raise concerns over Asda’s link to app offering high-interest loans to staff

An influential group of MPs has sought assurances that Asda is not “squeezing staff” to drive profit after it emerged they are being offered high-interest loans by Wagestream, a company in which the retailer’s owner has a stake.The business and trade select committee has written to Asda over its links to the “financial wellbeing app” that recently began offering the supermarket’s staff loans of up to £25,000. The default arrangements for Wagestream’s “workplace loans” involve debt repayments being directly deducted from workers’ pay packets.A holding company controlled by Asda’s private equity owner TDR Capital is a shareholder in Wagestream, which has been offering Asda workers a range of other services, including savings pots and wage advances, since 2023.Documents filed at Companies House show that the holding company, Bellis Financial Investments 2, is one of a number of shareholders in Wagestream, alongside former Wonga payday loan investor Balderton Capital, and social impact investors including the Joseph Rowntree Foundation via the Fair by Design Fund

1 day ago
A picture

Paramount Skydance reportedly preparing takeover bid for Warner Bros Discovery

Paramount Skydance is reportedly preparing a takeover offer for Warner Bros Discovery, in a bid to pull together two of the largest US legacy media conglomerates and Hollywood movie studios.Less than a month after Skydance, a production firm run by David Ellison, son of the billionaire tech mogul Larry Ellison, closed its merger with Paramount, the firm is considering other blockbuster deals.Combining Paramount with WBD would reshape the US entertainment and media industry, shifting prominent brands in TV, cinema and news – from South Park and Superman to CNN and 60 Minutes – together for the first time.Paramount is preparing a majority cash bid for WBD that would be backed by the Ellison family, according to the Wall Street Journal, which cited unnamed sources familiar with the situation. Paramount and WBD did not immediately respond to requests for comment

1 day ago
A picture

UK must heed Sir John Bell’s big pharma investment warning

Compare and contrast. Here is the opening line in the government’s response to news that the US pharmaceutical company Merck is scrapping its £1bn research centre in King’s Cross in London because it thinks the UK is not an internationally competitive venue. Whistling cheerfully, the Department for Science, Technology and Innovation managed to claim: “The UK has become the most attractive place to invest in the world.”And here is Sir John Bell, former regius professor of medicine at the University of Oxford and all-round grand guru of life sciences in the UK. He told Radio 4 he had spoken to several chief executives of large pharmaceutical companies in the past six months “and they’re all in the same space, and that is, they’re not going to do any more investing in the UK”

2 days ago
trendingSee all
A picture

Barclays boss urges UK ministers to limit public sector pay rises

about 22 hours ago
A picture

UK economy flatlines in July in grim news for Rachel Reeves

1 day ago
A picture

Larry Ellison briefly overtakes Elon Musk as world’s richest person

3 days ago
A picture

Snapchat allows drug dealers to operate openly on platform, finds Danish study

3 days ago
A picture

Leigh sweep sorry St Helens aside to confirm home playoff slot

about 15 hours ago
A picture

Canelo Álvarez and Terence Crawford hit 167½lb ahead of Las Vegas megafight

about 16 hours ago